Keyword: BlackThorn Therapeutics
BlackThorn Therapeutics raised $76 million to push targeted treatments for mood disorders into phase 2 studies.
In response to declining venture investment in some disease areas, BIO is releasing reports to identify barriers to innovation.
The co-founders of autoimmune biotech Receptos are back with BlackThorn, a startup that aims to succeed in treacherous neuro territory by using physiological measures, rather than just a qualitative clinician assessment, to better define the diseases and their populations.
The philosophy of Fierce 15 is a simple one: We want to see the best science combined with the brightest teams, and we want to see the promise that they hold in their hands has a genuine chance of being the Next Big Thing. Here are this year's standouts.
